Elisabet E Manasanch
Overview
Explore the profile of Elisabet E Manasanch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ndacayisaba L, Rappard K, Shishido S, Setayesh S, Tang G, Lin P, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362214
B-cell maturation antigen (BCMA), a key regulator of B-cell proliferation and survival, is highly expressed in almost all cases of plasma cell neoplasms and B-lymphoproliferative malignancies. BCMA is a robust...
12.
Alomari M, Kunacheewa C, Manasanch E
Leuk Lymphoma
. 2022 Oct;
64(2):261-272.
PMID: 36282671
Currently used stratification models in myeloma precursor disease as well as staging systems and response criteria in myeloma have limitations including failure to identify functionally high-risk myeloma patients. B-cell maturation...
13.
Manasanch E, Gertz M
Leuk Lymphoma
. 2022 Sep;
63(9):2021-2022.
PMID: 36093592
No abstract available.
14.
Afrough A, Alsfeld L, Milton D, Delgado R, Popat U, Nieto Y, et al.
Transplant Cell Ther
. 2022 May;
29(4):264.e1-264.e9.
PMID: 35605883
Despite remarkable progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) have disease that relapses. Allogeneic (allo-) hematopoietic cell transplantation (HCT)...
15.
Gaballa M, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner M, et al.
Bone Marrow Transplant
. 2022 May;
57(7):1142-1149.
PMID: 35523847
Bortezomib, lenalidomide, and dexamethasone (VRD) induction is standard prior to autologous hematopoietic cell transplantation (auto-HCT) in newly diagnosed, high-risk multiple myeloma (ND-HRMM). Carfilzomib (K) is another proteasome inhibitor approved for...
16.
Mohan M, Becnel M, Shah U, Dong H, Gundarlapalli S, Peterson T, et al.
Am J Hematol
. 2022 Apr;
97(7):E276-E280.
PMID: 35472167
No abstract available.
17.
Clay-Gilmour A, Chattopadhyay S, Hildebrandt M, Thomsen H, Weinhold N, Vodicka P, et al.
Blood Cancer J
. 2022 Apr;
12(4):60.
PMID: 35418122
No abstract available.
18.
Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, et al.
Transplant Cell Ther
. 2022 Mar;
28(6):307.e1-307.e8.
PMID: 35331973
Induction therapy with a triplet regimen, followed by high-dose therapy and autologous hematopoietic stem cell transplantation (auto-HCT), is the standard of care for newly diagnosed, transplant-eligible patients with multiple myeloma...
19.
Gaballa M, Ma J, Tanner M, Al-Juhaishi T, Bashir Q, Srour S, et al.
Leuk Lymphoma
. 2021 Oct;
63(3):710-721.
PMID: 34686083
Standard-of-care for newly-diagnosed, autologous hematopoietic stem cell transplantation (auto-HCT)-eligible, multiple myeloma (MM) patients includes bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by melphalan 200 mg/m (Mel200)-conditioned auto-HCT and lenalidomide maintenance....
20.
Kunacheewa C, Manasanch E
Expert Rev Hematol
. 2021 Sep;
14(12):1059-1069.
PMID: 34550841
Introduction: Multiple myeloma is preceded by the early stages: monoclonal gammopathy of unknown significance (M.G.U.S.) and smoldering myeloma (S.M.M.), which are less genomically complex and where patients are overall healthier...